Alkem Laboratories Ltd. on Thursday reported a 4.2% year-on-year (YoY) rise in fourth-quarter net profit (after minority interest) to ₹305.9 crore.
The Mumbai-based pharmaceutical company’s total revenue from operations for the fourth quarter grew by 7.1% year-on-year to ₹3143.8 crore.
For the fourth quarter, however, the EBITDA margin contracted to 12.4% from 13.7% in the same period last year.
The company’s India sales were a significant contributor, rising 8.1% to ₹2135.5 crore. International sales also saw an increase, growing by 7.2% to ₹974.7 crore.
For the full fiscal year, net profit climbed 20.6% to ₹2165.5 crore. Alkem’s total revenue from operations increased by a modest 2.3% to ₹12,964.5 crore. This was primarily driven by a 6.5% growth in India sales, which reached ₹8983.7 crore. However, international sales for the year saw a de-growth of 4.5%.
The company's EBITDA margin for the full year expanded by 170 basis points to 19.4%. Annual EBITDA increased by 11.9% to ₹2512.2 crore.
In the Indian market, Alkem's growth was 6.8% for the full year, compared to the Indian Pharmaceutical Market's (IPM) growth of 7.7%, according to IQVIA data. The company's acute segment outperformed the IPM by 30 basis points in FY25.
Research and development expenses for FY25 were 4.3% of total revenue. The company filed 9 abbreviated new drug applications (ANDAs) with the USFDA and received 14 approvals during the year.
The company's cash and bank balance stood at ₹4620 crore as of March 31, 2025.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
